Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies

Authors

B Garmezy
Brendan Curti, ProvidenceFollow
See full list of authors in comments

Document Type

Abstract

Publication Date

10-20-2023

Keywords

oregon; chiles

Clinical Institute

Cancer

Department

Oncology

Department

Hematology

Comments

Garmezy B, Kambhampati S, Curti B, Reimers M, Caimi P, Diefenbach C, Heath E, Jonasch E, Park S, Kornblum N, Li W, Li N, Spurgeon S, Vaishampayan UN, Ye D, Zhang L, Zhao W, Chen Z, Hunder N, Ma S, Song E, Call JA. SITC Annual Meeting; November 1-5; San Diego, CA. 2023;11(Suppl 1): 718.

Recommended Citation

Garmezy, B; Curti, Brendan; and See full list of authors in comments, "Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies" (2023). Articles, Abstracts, and Reports. 8363.
https://digitalcommons.providence.org/publications/8363